University of California San Francisco

Schrepfer 300Dpi
Sonja
Schrepfer
MD, PhD

Professor of Surgery
Division of Cardiothoracic Surgery
Co-Director, Transplant and Stem Cell Immunobiology (TSI) Lab

Address

513 Parnassus Avenue, MSB, #001
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-502-8742

Biography

Sonja Schrepfer, M.D., Ph.D., Professor of Surgery, founded the Transplant and Stem Cell Immunobiology (TSI) Lab in 2009 in Germany. In 2016, she joined the faculty of the Department of Surgery at the University of California San Francisco. She is also Co-Director of the TSI Lab at UCSF.

Dr. Schrepfer's research career has been dedicated to making fundamental discovers in stem cell immunology, transplant and cardiovascular immunobiology. Her lab currently works on immunobiological mechanisms of pluripotent stem cells (mouse and human). One project uses e.g. a combination of molecular/cellular biology, genomic/epigenomic profiling, tissue engineering, and molecular imaging technologies to better understand stem cell biology in vitro and in vivo. She has made significant contributions in the field of immunological barriers in regenerative medicine and in identifying novel immunobiological targets involved in cardiovascular diseases.

The TSI Lab is also investigating the vascular biology of “mice from space”; that is mice that have spent time at the international space station (ISS). This research will provide insight into what physiological effects time in outer space might have on astronauts, with potentially important implications for future longer-term missions, and has the possibility to open the door to fascinating new discoveries that could be used in earth-bound cardiovascular research.

Education

Education

University of Wuerzburg and Munich, Germany MD 10/2001 Medicine, Immunology

University of Wuerzburg, Germany Doctoral Thesis 05/2002 Medicine, Immunology

University of Hamburg, Germany and Stanford University, Stanford, CA PhD 01/2007 Experimental Cardiac Surgery, Transplant Immunobiology

Stanford University, Stanford, CA Postdoctoral Training and Instructor 02/2009 Cardiothoracic Surgery, Transplant Immunobiology

Fellowships

2005 - 2007 Postdoctoral Fellow, Transplant Immunology Laboratory, Stanford University, School of Medicine, CT Surgery. Advisor: Dr. Robert C. Robbins

Postdoctoral Training

2007 - 2009 Instructor, Transplant Immunology Laboratory, Stanford University, School of Medicine, CT Surgery

2009-2015 Professor and Founder, Transplant and Stem Cell Immunobiology (TSI) Laboratory, University Heart Center Hamburg, Germany

Foreign Languages Spoken

German, French

Grants and Funding

  • Hypo-immunogenic cardiomyocytes for myocardial repair | NIH | 2018-08-01 - 2022-06-30 | Role: Co-Principal Investigator
  • Microgravity as model for immunological senescence and its impact on tissue stem cells and regeneration | NIH | 2017-06-15 - 2022-06-30 | Role: Principal Investigator
  • Microgravity as model for immunological senescence and its impact on tissue stem cells and regeneration | NIH | 2017-06-15 - 2020-02-29 | Role: Principal Investigator

Research Narrative

Dr. Schrepfer's research aims to understand the critical immunological barrier that presently precludes the successful application of cell-based regenerative therapy. Her TSI Lab has made seminal contributions to the field, including the first description of the antigenicity of mitochondria in embryonic stem cells derived by somatic cell nucleus transfer (SCNT). Currently, her group is interested in understanding the molecular, cellular, and epigenetic landscape changes after transplantation of stem cells and their derivates and we are aiming to decrease the immunogenic potential of PSCs.

The lab has also discovered novel pathways involved in the development of vascular intimal hyperplasia. Myointimal hyperplasia is a pathological process of the vascular system characterized by abnormal proliferation of smooth muscle cells of the vascular wall that leads to luminal obliteration and subsequent ischemia. Myointimal hyperplasia may occur in patients after vessel injury during medical procedures (e.g. after balloon dilation or stent placement) or after pathological injury of the blood vessel (e.g. due to inflammation or toxic exposure). It can cause graft failure and in-stent restenosis. To help prevent this and increase the success of treatments for coronary heart disease, Dr. Schrepfer's lab has also developed novel humanized models to study the development of intimal hyperplasia.

Transplant immunology after heart and lung transplantation is another area the lab is exploring with particular focus on translational research and investigation of underlying mechanisms of acute and chronic graft rejection. Novel drug discoveries will benefit our patients tremendously.

Research Interests

Pluripotent Stem Cell Immunobiology

Cardiovascular Mechanisms involved in Vessel Stenosis

Transplant Immunology

Vascular Biology of Mice During Space Travel

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 100
  1. Leukotriene B4: A potential mediator and biomarker for cardiac allograft vasculopathy.
    Wang D, Tediashvili G, Kim D, Hu X, Luikart H, Renne T, Tian A, Nadeau KC, Velden J, Schrepfer S, Khush KK| | PubMed
  2. Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.
    Hu X, White K, Young C, Olroyd AG, Kievit P, Connolly AJ, Deuse T, Schrepfer S| | PubMed
  3. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity.
    Gravina A, Tediashvili G, Zheng Y, Iwabuchi KA, Peyrot SM, Roodsari SZ, Gargiulo L, Kaneko S, Osawa M, Schrepfer S, Deuse T| | PubMed
  4. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques.
    Hu X, White K, Olroyd AG, DeJesus R, Dominguez AA, Dowdle WE, Friera AM, Young C, Wells F, Chu EY, Ito CE, Krishnapura H, Jain S, Ankala R, McGill TJ, Lin A, Egenberger K, Gagnon A, Michael Rukstalis J, Hogrebe NJ, Gattis C, Basco R, Millman JR, Kievit P, Davis MM, Lanier LL, Connolly AJ, Deuse T, Schrepfer S| | PubMed
  5. Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice.
    Hu X, Gattis C, Olroyd AG, Friera AM, White K, Young C, Basco R, Lamba M, Wells F, Ankala R, Dowdle WE, Lin A, Egenberger K, Rukstalis JM, Millman JR, Connolly AJ, Deuse T, Schrepfer S| | PubMed
  6. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice.
    Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, Bandoro C, Tham E, Chu EY, Young C, Wells F, Basco R, Friera A, Kangeyan D, Beauchesne P, Dowdle WE, Deuse T, Fry TJ, Foster AE, Schrepfer S| | PubMed
  7. Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression.
    Gravina A, Tediashvili G, Rajalingam R, Quandt Z, Deisenroth C, Schrepfer S, Deuse T| | PubMed
  8. Author Correction: Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.
    Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Reichenspurner H, Davis MM, Lanier LL, Schrepfer S| | PubMed
  9. Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice.
    Deuse T, Tediashvili G, Hu X, Gravina A, Tamenang A, Wang D, Connolly A, Mueller C, Mallavia B, Looney MR, Alawi M, Lanier LL, Schrepfer S| | PubMed
  10. Immunomodulation Therapy Using Tolerogenic Macrophages in a Rodent Model of Pulmonary Hypertension.
    Guihaire J, Deuse T, Wang D, Spin JM, Blankenberg FG, Fadel E, Reichenspurner H, Schrepfer S| | PubMed
  11. The SIRPα-CD47 immune checkpoint in NK cells.
    Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, Gravina A, Tediashvili G, Nguyen VQ, Liu Y, Valantine H, Lanier LL, Schrepfer S| | PubMed
  12. Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact.
    da Silveira WA, Fazelinia H, Rosenthal SB, Laiakis EC, Kim MS, Meydan C, Kidane Y, Rathi KS, Smith SM, Stear B, Ying Y, Zhang Y, Foox J, Zanello S, Crucian B, Wang D, Nugent A, Costa HA, Zwart SR, Schrepfer S, Elworth RAL, Sapoval N, Treangen T, MacKay M, Gokhale NS, Horner SM, Singh LN, Wallace DC, Willey JS, Schisler JC, Meller R, McDonald JT, Fisch KM, Hardiman G, Taylor D, Mason CE, Costes SV, Beheshti A| | PubMed
  13. The H-Y Antigen in Embryonic Stem Cells Causes Rejection in Syngeneic Female Recipients.
    Hu X, Kueppers ST, Kooreman NG, Gravina A, Wang D, Tediashvili G, Schlickeiser S, Frentsch M, Nikolaou C, Thiel A, Marcus S, Fuchs S, Velden J, Reichenspurner H, Volk HD, Deuse T, Schrepfer S| | PubMed
  14. A Cryoinjury Model to Study Myocardial Infarction in the Mouse.
    Wang D, Tediashvili G, Hu X, Gravina A, Marcus SG, Zhang H, Olgin JE, Deuse T, Schrepfer S| | PubMed
  15. De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans.
    Deuse T, Hu X, Agbor-Enoh S, Koch M, Spitzer MH, Gravina A, Alawi M, Marishta A, Peters B, Kosaloglu-Yalcin Z, Yang Y, Rajalingam R, Wang D, Nashan B, Kiefmann R, Reichenspurner H, Valantine H, Weissman IL, Schrepfer S| | PubMed
  16. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.
    Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Reichenspurner H, Davis MM, Lanier LL, Schrepfer S| | PubMed
  17. Dead space ventilation promotes alveolar hypocapnia reducing surfactant secretion by altering mitochondrial function.
    Kiefmann M, Tank S, Tritt MO, Keller P, Heckel K, Schulte-Uentrop L, Olotu C, Schrepfer S, Goetz AE, Kiefmann R| | PubMed
  18. Exosomal profiling in cardiac allograft rejection: Best basic science article in 2018.
    Kulkarni HS, Diamond JM, Schrepfer S, Cantu E| | PubMed
  19. No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart.
    Weinberger F, Nicol P, Starbatty J, Stubbendorff M, Becher PM, Schrepfer S, Eschenhagen T| | PubMed
  20. Sphingosine-1-phosphate receptor 1 regulates neointimal growth in a humanized model for restenosis.
    Braetz J, Becker A, Geissen M, Larena-Avellaneda A, Schrepfer S, Daum G| | PubMed
  21. Optimization of oxygenation during ex vivo lung perfusion-Best basic science article in 2017.
    Shaver CM, Diamond JM, Schrepfer S, Cantu E| | PubMed
  22. Balloon-based Injury to Induce Myointimal Hyperplasia in the Mouse Abdominal Aorta.
    Tediashvili G, Wang D, Reichenspurner H, Deuse T, Schrepfer S| | PubMed
  23. Opportunities for Lung Repair and Regeneration: An Overview.
    Schrepfer S| | PubMed
  24. Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study.
    Miller KK, Wang D, Hu X, Hua X, Deuse T, Neofytou E, Renne T, Velden J, Reichenspurner H, Schrepfer S, Bernstein D| | PubMed
  25. Differences in Vascular Response between Balloon Overstretch and Stent Overexpansion in Nonatherosclerotic Porcine Coronary Arteries.
    Mitsutake Y, Reifart J, Pyun WB, Lyons JK, Deuse T, Schrepfer S, Ikeno F| | PubMed
  26. The ubiquitin-proteasome system: A potential therapeutic target for heart failure.
    Barac YD, Emrich F, Krutzwakd-Josefson E, Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A, Mohr FW, Aravot D, Taylor DA| | PubMed
  27. Vein Interposition Model: A Suitable Model to Study Bypass Graft Patency.
    Wang D, Tediashvili G, Pecha S, Reichenspurner H, Deuse T, Schrepfer S| | PubMed
  28. Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder.
    Guihaire J, Itagaki R, Stubbendorff M, Hua X, Deuse T, Ullrich S, Fadel E, DorfmĂŒller P, Robbins RC, Reichenspurner H, Schumacher U, Schrepfer S| | PubMed
  29. miR-126: a potential new key player in hypoxia and reperfusion?
    Guenther SP, Schrepfer S| | PubMed
  30. The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation.
    Deuse T, Hua X, Stubbendorff M, Spin JM, Neofytou E, Taylor V, Chen Y, Park G, Fink JB, Renne T, Kiefmann M, Kiefmann R, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  31. "Bioengineered lungs" Best science paper in JHLT 2014-2015.
    Schrepfer S, Cantu E, Gandy K, Baan CC, West LJ| | PubMed
  32. miR-21 promotes fibrosis in an acute cardiac allograft transplantation model.
    Gupta SK, Itagaki R, Zheng X, Batkai S, Thum S, Ahmad F, Van Aelst LN, Sharma A, Piccoli MT, Weinberger F, Fiedler J, Heuser M, Heymans S, Falk CS, Förster R, Schrepfer S, Thum T| | PubMed
  33. Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade.
    Guihaire J, Deuse T, Wang D, Fadel E, Reichenspurner H, Schrepfer S| | PubMed
  34. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats.
    Wang H, Weihrauch D, Kersten JR, Toth JM, Passerini AG, Rajamani A, Schrepfer S, LaDisa JF| | PubMed
  35. Distal Airway Stem Cells are Essential for Lung Regeneration.
    Deuse T, Schrepfer S| | PubMed
  36. Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis.
    Wang D, Deuse T, Stubbendorff M, Chernogubova E, Erben RG, Eken SM, Jin H, Li Y, Busch A, Heeger CH, Behnisch B, Reichenspurner H, Robbins RC, Spin JM, Tsao PS, Schrepfer S, Maegdefessel L| | PubMed
  37. Advancing knowledge of right ventricular pathophysiology in chronic pressure overload: Insights from experimental studies.
    Guihaire J, Noly PE, Schrepfer S, Mercier O| | PubMed
  38. Effective Apical Infection of Differentiated Human Bronchial Epithelial Cells and Induction of Proinflammatory Chemokines by the Highly Pneumotropic Human Adenovirus Type 14p1.
    Lam E, Ramke M, Warnecke G, Schrepfer S, Kopfnagel V, Dobner T, Heim A| | PubMed
  39. Mesenchymal stromal cell therapy: different sources exhibit different immunobiological properties.
    Neofytou E, Deuse T, Beygui RE, Schrepfer S| | PubMed
  40. Immunobiology of fibrin-based engineered heart tissue.
    Conradi L, Schmidt S, Neofytou E, Deuse T, Peters L, Eder A, Hua X, Hansen A, Robbins RC, Beygui RE, Reichenspurner H, Eschenhagen T, Schrepfer S| | PubMed
  41. Impaired Endothelial Regeneration Through Human Parvovirus B19-Infected Circulating Angiogenic Cells in Patients With Cardiomyopathy.
    Schmidt-Lucke C, Zobel T, Schrepfer S, Kuhl U, Wang D, Klingel K, Becher PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Escher F, Holinski S, Volk HD, Schultheiss HP, Tschope C| | PubMed
  42. Erratum: miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development.
    Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nakagami F, Heymann HM, Chernogubova E, Jin H, Roy J, Hultgren R, Caidahl K, Schrepfer S, Hamsten A, Eriksson P, McConnell MV, Dalman RL, Tsao PS| | PubMed
  43. SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts.
    Deuse T, Wang D, Stubbendorff M, Itagaki R, Grabosch A, Greaves LC, Alawi M, GrĂŒnewald A, Hu X, Hua X, Velden J, Reichenspurner H, Robbins RC, Jaenisch R, Weissman IL, Schrepfer S| | PubMed
  44. miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development.
    Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nakagami F, Nagakami F, Heymann HM, Chernogubova E, Chernugobova E, Jin H, Roy J, Hultgren R, Caidahl K, Schrepfer S, Hamsten A, Eriksson P, McConnell MV, Dalman RL, Tsao PS| | PubMed
  45. Inducing myointimal hyperplasia versus atherosclerosis in mice: an introduction of two valid models.
    Stubbendorff M, Hua X, Deuse T, Ali Z, Reichenspurner H, Maegdefessel L, Robbins RC, Schrepfer S| | PubMed
  46. Dichloroacetate prevents restenosis in preclinical animal models of vessel injury.
    Deuse T, Hua X, Wang D, Maegdefessel L, Heeren J, Scheja L, Bolaños JP, Rakovic A, Spin JM, Stubbendorff M, Ikeno F, LÀnger F, Zeller T, Schulte-Uentrop L, Stoehr A, Itagaki R, Haddad F, Eschenhagen T, Blankenberg S, Kiefmann R, Reichenspurner H, Velden J, Klein C, Yeung A, Robbins RC, Tsao PS, Schrepfer S| | PubMed
  47. The CaÂČâș-activated Kâș channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.
    Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H| | PubMed
  48. Immunological properties of extraembryonic human mesenchymal stromal cells derived from gestational tissue.
    Stubbendorff M, Deuse T, Hua X, Phan TT, Bieback K, Atkinson K, Eiermann TH, Velden J, Schröder C, Reichenspurner H, Robbins RC, Volk HD, Schrepfer S| | PubMed
  49. Small animal models of experimental obliterative bronchiolitis.
    Jungraithmayr W, Jang JH, Schrepfer S, Inci I, Weder W| | PubMed
  50. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
    Hua X, Deuse T, Chen YJ, Wulff H, Stubbendorff M, Köhler R, Miura H, LÀnger F, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  51. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
    Deuse T, Hua X, Taylor V, Stubbendorff M, Baluom M, Chen Y, Park G, Velden J, Streichert T, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  52. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.
    Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC| | PubMed
  53. Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis.
    Hua X, Deuse T, Michelakis ED, Haromy A, Tsao PS, Maegdefessel L, Erben RG, Bergow C, Behnisch BB, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  54. Localization of Islet-1-positive cells in the healthy and infarcted adult murine heart.
    Weinberger F, Mehrkens D, Friedrich FW, Stubbendorff M, Hua X, MĂŒller JC, Schrepfer S, Evans SM, Carrier L, Eschenhagen T| | PubMed
  55. Human leukocyte antigen I knockdown human embryonic stem cells induce host ignorance and achieve prolonged xenogeneic survival.
    Deuse T, Seifert M, Phillips N, Fire A, Tyan D, Kay M, Tsao PS, Hua X, Velden J, Eiermann T, Volk HD, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  56. Immunobiology of naĂŻve and genetically modified HLA-class-I-knockdown human embryonic stem cells.
    Deuse T, Seifert M, Phillips N, Fire A, Tyan D, Kay M, Tsao PS, Hua X, Velden J, Eiermann T, Volk HD, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  57. Assessment of physiologic natural killer cell cytotoxicity in vitro.
    Duske H, Sputtek A, Binder T, Kröger N, Schrepfer S, Eiermann T| | PubMed
  58. Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo.
    Michelfelder S, Varadi K, Raupp C, Hunger A, Körbelin J, Pahrmann C, Schrepfer S, MĂŒller OJ, Kleinschmidt JA, Trepel M| | PubMed
  59. Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT).
    Conradi L, Pahrmann C, Schmidt S, Deuse T, Hansen A, Eder A, Reichenspurner H, Robbins RC, Eschenhagen T, Schrepfer S| | PubMed
  60. Prevention of transplant coronary artery disease by prenylation inhibitors.
    Stein W, Schrepfer S, Itoh S, Kimura N, Velotta J, Palmer O, Bartos J, Wang X, Robbins RC, Fischbein MP| | PubMed
  61. Orthotopic aortic transplantation: a rat model to study the development of chronic vasculopathy.
    Stubbendorff M, Deuse T, Hammel A, Robbins RC, Reichenspurner H, Schrepfer S| | PubMed
  62. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells.
    Deuse T, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann T, Phan TT, Volk HD, Reichenspurner H, Robbins RC, Schrepfer S| | PubMed
  63. Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon injury and stenting.
    Deuse T, Koyanagi T, Erben RG, Hua X, Velden J, Ikeno F, Reichenspurner H, Robbins RC, Mochly-Rosen D, Schrepfer S| | PubMed
  64. Non-volume-loaded heart provides a more relevant heterotopic transplantation model.
    Tang-Quan KR, Bartos J, Deuse T, Churchill E, SchÀfer H, Reichenspurner H, Mochly-Rosen D, Robbins RC, Schrepfer S| | PubMed
  65. Heterotopic and orthotopic tracheal transplantation in mice used as models to study the development of obliterative airway disease.
    Hua X, Deuse T, Tang-Quan KR, Robbins RC, Reichenspurner H, Schrepfer S| | PubMed
  66. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation.
    Deuse T, Blankenberg F, Haddad M, Reichenspurner H, Phillips N, Robbins RC, Schrepfer S| | PubMed
  67. LAD-ligation: a murine model of myocardial infarction.
    Kolk MV, Meyberg D, Deuse T, Tang-Quan KR, Robbins RC, Reichenspurner H, Schrepfer S| | PubMed
  68. Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium.
    Govaert JA, Swijnenburg RJ, Schrepfer S, Xie X, van der Bogt KE, Hoyt G, Stein W, Ransohoff KJ, Robbins RC, Wu JC| | PubMed
  69. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.
    Deuse T, Peter C, Fedak PW, Doyle T, Reichenspurner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S| | PubMed
  70. Imaging in-stent restenosis: an inexpensive, reliable, and rapid preclinical model.
    Deuse T, Ikeno F, Robbins RC, Schrepfer S| | PubMed
  71. A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection.
    Velotta JB, Deuse T, Haddad M, Masuda E, Park G, Carroll D, Taylor V, Robbins RC, Schrepfer S| | PubMed
  72. Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart.
    van der Bogt KE, Schrepfer S, Yu J, Sheikh AY, Hoyt G, Govaert JA, Velotta JB, Contag CH, Robbins RC, Wu JC| | PubMed
  73. In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation.
    Swijnenburg RJ, Schrepfer S, Cao F, Pearl JI, Xie X, Connolly AJ, Robbins RC, Wu JC| | PubMed
  74. Comparison of different adult stem cell types for treatment of myocardial ischemia.
    van der Bogt KE, Sheikh AY, Schrepfer S, Hoyt G, Cao F, Ransohoff KJ, Swijnenburg RJ, Pearl J, Lee A, Fischbein M, Contag CH, Robbins RC, Wu JC| | PubMed
  75. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts.
    Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, Haddad M, Connolly AJ, Davis MM, Robbins RC, Wu JC| | PubMed
  76. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
    Deuse T, Velotta JB, Hoyt G, Govaert JA, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier MP, Robbins RC, Schrepfer S| | PubMed
  77. Prevention and inhibition but not reversion of chronic allograft vasculopathy by FK778.
    Deuse T, Hoyt G, Koyanagi T, Robbins RC, Schrepfer S| | PubMed
  78. Introducing the first polymer-free leflunomide eluting stent.
    Deuse T, Erben RG, Ikeno F, Behnisch B, Boeger R, Connolly AJ, Reichenspurner H, Bergow C, Pelletier MP, Robbins RC, Schrepfer S| | PubMed
  79. Inhibition of aldehyde dehydrogenase type 2 attenuates vasodilatory action of nitroglycerin in human veins.
    Huellner MW, Schrepfer S, Weyand M, Weiner H, Wimplinger I, Eschenhagen T, Rau T| | PubMed
  80. Failed induction of heme oxygenase 1 in endothelial cells exposed to the hemoglobin based oxygen carrier Oxyglobin.
    Rempf C, Ritter A, Schrepfer S, Freitag M, Standl T, Gottschalk A| | PubMed
  81. Right atrial mass after primary repair of an atrial septal defect: thrombus masquerading as a myxoma.
    Sheikh AY, Schrepfer S, Stein W, West J, Lombard J, Burdon T, Pinsker B, Pelletier MP| | PubMed
  82. Techniques for experimental heterotopic and orthotopic tracheal transplantations - When to use which model?
    Deuse T, Schrepfer S, Reichenspurner H, Hoyt G, Fischbein MP, Robbins RC, Pelletier MP| | PubMed
  83. Coincidence of aortic valve stenosis and regurgitation and multiple cardiac papillary fibroelastomas in a young male adult.
    Sydow K, Schrepfer S, Franzen O, Detter C, Willems S, Meinertz T, Reichenspurner H| | PubMed
  84. Simplified protocol to isolate, purify, and culture expand mesenchymal stem cells.
    Schrepfer S, Deuse T, Lange C, Katzenberg R, Reichenspurner H, Robbins RC, Pelletier MP| | PubMed
  85. Experimental orthotopic tracheal transplantation: The Stanford technique.
    Schrepfer S, Deuse T, Hoyt G, Sheikh AY, Hoffmann J, Reichenspurner H, Robbins RC, Pelletier MP| | PubMed
  86. FK778 in experimental xenotransplantation: a detailed analysis of drug efficacy.
    Schrepfer S, Deuse T, Koch-Nolte F, Krieger T, Haddad M, SchÀfer H, Pelletier MP, Robbins RC, Reichenspurner H| | PubMed
  87. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?
    Schrepfer S, Deuse T, Sultan KR, Haddad M, Böger R, MĂŒnzel T, SchĂ€fer H, Pelletier MP, Robbins RC, Reichenspurner H| | PubMed
  88. The selective estrogen receptor-beta agonist biochanin A shows vasculoprotective effects without uterotrophic activity.
    Schrepfer S, Deuse T, MĂŒnzel T, SchĂ€fer H, Braendle W, Reichenspurner H| | PubMed
  89. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase.
    Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, Sydow K, Lau D, Szöcs K, Klinke A, Kubala L, Berglund L, Schrepfer S, Deuse T, Haddad M, Risius T, Klemm H, Reichenspurner HC, Meinertz T, Heitzer T| | PubMed
  90. Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease.
    Deuse T, Schrepfer S, Koch-Nolte F, Haddad M, SchÀfer H, Detter C, Reichenspurner H| | PubMed
  91. The phytoestrogen biochaninA weakens acute cardiac allograft rejection without affecting the reproductive system.
    Schrepfer S, Deuse T, SchÀfer H, Koch-Nolte F, Braendle W, Reichenspurner H| | PubMed
  92. FK778 and tacrolimus prevent the development of obliterative airway disease after heterotopic rat tracheal transplantation.
    Deuse T, Schrepfer S, Koch-Nolte F, Haddad M, Schwedhelm E, Böger R, SchÀfer H, Detter C, Reichenspurner H| | PubMed
  93. FK778, a novel immunosuppressive agent, reduces early adhesion molecule up-regulation and prolongs cardiac allograft survival.
    Schrepfer S, Deuse T, SchÀfer H, Reichenspurner H| | PubMed
  94. FK778 attenuates lymphocyte-endothelium interaction after cardiac transplantation: in vivo and in vitro studies.
    Deuse T, Schrepfer S, SchÀfer H, Koch-Nolte F, Schwedhelm E, Böger RH, Reichenspurner H| | PubMed
  95. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent.
    Deuse T, Schrepfer S, Reichenspurner H| | PubMed
  96. Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model.
    Deuse T, Schrepfer S, Reichenspurner H| | PubMed
  97. Successful resection of a symptomatic right ventricular lipoma.
    Schrepfer S, Deuse T, Detter C, Treede H, Koops A, Boehm DH, Willems S, Lacour-Gayet F, Reichenspurner H| | PubMed
  98. New technique for chest opening in mice: U-sternotomy.
    Schrepfer S, Deuse T, Reichenspurner H| | PubMed
  99. Myoblasts survive intracardiac transfer and divide further after transplantation.
    Gulbins H, Schrepfer S, Uhlig A, Goldemund A, Oberhoffer M, Reichenspurner H, Meiser B, Reichart B| | PubMed
  100. Wildlife ecologist: aldo leopoid.
    Schrepfer SR| | PubMed